Antiparasitic Activities and Toxicities of Individual Enantiomers of the 8-Aminoquinoline 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4-Dichlorophenoxy]Quinoline Succinate
Open Access
- 1 June 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (6) , 2130-2137
- https://doi.org/10.1128/aac.00645-07
Abstract
8-Aminoquinolines are an important class of antiparasitic agents, with broad utility and excellent efficacy, but also limitations due to hematological toxicities, primarily methemoglobinemia and hemolysis. One representative from this class, (±)-8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate (NPC1161C), proved extremely efficacious in animal models of malaria and pneumocystis pneumonia. This racemic mixture was separated into its component enantiomers by chemical and chromatographic means. The enantiomers were evaluated for antiparasitic activity in murine models of Plasmodium berghei , Pneumocystis carinii , and Leishmania donovani infection, as well as the propensity to elicit hematotoxicity in dogs. The (−)-enantiomer NPC1161B was found to be more active (by severalfold, depending on the dosing regimen) than the (+)-enantiomer NPC1161A in all of these murine models. In addition, the (−) enantiomer showed markedly reduced general toxicity in mice and reduced hematotoxicity in the dog model of methemoglobinemia. It is concluded that the configuration at the asymmetric center in the 8-amino side chain differentially affects efficacy and toxicity profiles and thus may be an important determinant of the “therapeutic window” for compounds in this class.Keywords
This publication has 49 references indexed in Scilit:
- GC-MS Analysis of the 8-Aminoquinoline Antimalarial [NPC1161] and its Carboxy Metabolite in Plasma and Red Blood Cells of PrimatesChromatographia, 2006
- In Vitro and In Vivo Models of Pneumocyustis cariniiThe Journal of Eukaryotic Microbiology, 1997
- Clindamycin and Primaquine Therapy for Mild-to-Moderate Episodes of Pneumocystis carinii Pneumonia in Patients with AIDS: AIDS Clinical Trials Group 044Clinical Infectious Diseases, 1994
- Clindamycin/Primaquine Versus Trimethoprim-Sulfamethoxazole as Primary Therapy for Pneumocystis carinii Pneumonia in AIDS: A Randomized, Double-Blind Pilot TrialClinical Infectious Diseases, 1993
- Inoculated mouse model of Pneumocystis carinii infectionDiagnostic Microbiology and Infectious Disease, 1992
- Clindamycin/primaquine for treatment ofPneumocystis carinii pneumonia in AIDSEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Clindamycin and primaquine as primary treatment for mild and moderately severePneumocystis carinii pneumonia in patients with AIDSEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Clindamycin/Primaquine Therapy and Secondary Prophylaxis Against Pneumocystis carinii Pneumonia in Patients With AIDSSouthern Medical Journal, 1990
- Antimalarial activity and inhibition of monoamine oxidases A and B by exo‐erythrocytic antimalarialsFEBS Letters, 1987
- Studies in the Quinoline Series. III. The Preparation of Some 8-(ι-Alkylaminoalkylamino)-quinolines1Journal of the American Chemical Society, 1946